Kimia Biosciences Intrinsic Value
Kimia Biosciences intrinsic value. Kimia Biosciences (KIMIABL) median intrinsic value is ₹66.40 from 9 valuation models (range ₹10–₹83), vs current price ₹33.20 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Compare with Kimia Biosciences value estimation to assess whether the stock is under or overvalued.
KIMIABL Valuation Methods Summary — DCF, Graham Number & P/E
Kimia Biosciences intrinsic value across 9 models vs current price ₹33.20 — upside/downside and value range per method. Read KIMIABL dividend history for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹35.20 | ₹28.16 - ₹42.24 | +6.0% | EPS: ₹1.60, Sector P/E: 22x |
| Book Value Method | asset | ₹72.00 | ₹64.80 - ₹79.20 | +116.9% | Book Value/Share: ₹36.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹66.40 | ₹59.76 - ₹73.04 | +100.0% | Revenue/Share: ₹226.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹66.40 | ₹59.76 - ₹73.04 | +100.0% | EBITDA: ₹15.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹83.00 | ₹66.40 - ₹99.60 | +150.0% | CF Growth: 11.2%, Discount: 15% |
| PEG Ratio Method | growth | ₹10.24 | ₹9.22 - ₹11.26 | -69.2% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹23.59 | ₹21.23 - ₹25.95 | -28.9% | Revenue Growth: -3.4%, Adj P/E: 14.7x |
| ROE Based Valuation | profitability | ₹66.40 | ₹59.76 - ₹73.04 | +100.0% | ROE: 38.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹36.00 | ₹32.40 - ₹39.60 | +8.4% | EPS: ₹1.60, BVPS: ₹36.00 |
KIMIABL Intrinsic Value vs Market Price — All Valuation Models
Kimia Biosciences fair value range ₹10–₹83 vs current market price ₹33.20 across 9 valuation models. For current market price and key ratios, visit KIMIABL screener.
KIMIABL Intrinsic Value Analysis — Undervalued or Overvalued?
Kimia Biosciences median intrinsic value ₹66.40, current price ₹33.20 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of KIMIABL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kimia Biosciences (KIMIABL) is ₹66.40 (median value). With the current market price of ₹33.20, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹10.24 to ₹83.00, indicating ₹10.24 - ₹83.00.
Is KIMIABL undervalued or overvalued?
Based on our multi-method analysis, Kimia Biosciences (KIMIABL) appears to be trading below calculated value by approximately 100.0%.
KIMIABL Financial Health — Key Ratios vs Industry Benchmarks
Kimia Biosciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.67 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 38.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.10x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
KIMIABL Cash Flow Quality — Operating & Free Cash Flow
Kimia Biosciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹11 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹21 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹15 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-7 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |